Clinical trials: Varicella Zoster
Post Herpetic Neuralgia
Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia
The purpose of this study is to investigate whether NXN-462, a selective nNOS inhibitor, is effective in reducing pain levels in patients with post-herpetic neuralgia.
- Trial name
- NCT01748877
- Testing
- NXN-462
- Where
- 25 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- NeurAxon Inc.
Herpes Zoster
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determine if they were immunogenic…
- Trial name
- NCT00696709
- Testing
- Comparator: V212
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis, Hypogammaglobulinemia
Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis
B cells are considered major contributors to multiple sclerosis (MS) pathogenesis, a role that has taken on renewed importance with the advent of B-cell-depleting therapies.
- Trial name
- NCT04283747
- Testing
- Serum immunoglobulin titer
- Where
- Iran
- Volunteers
- 170 people
- Sponsor
- Mazandaran University of Medical Sciences
Post Herpetic Neuralgia (PHN)
Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN).
- Trial name
- NCT07123987
- Testing
- transcutaneous auricular vagus nerve stimulation (taVNS), traditional medical treatment for PHN
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Mohamed Hosny Ismail Easa
Measles, Mumps
Safety Study of ProQuad® rHA in Infants (V221-037)
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured with recombinant human albumin (rHA) when administered to children in their second year of life.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00560755
- Testing
- ProQuad®
- Volunteers
- 3,388 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Prevention of Herpes Zoster (HZ)
Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
This is a Phase 1, first in human (FIH), randomised, active-controlled, double-blind study designed to assess the safety and tolerability and explore preliminary efficacy of the EG-HZ vaccine.
- Trial name
- NCT04210752
- Testing
- Treatment 1 (EG-HZ-001), Treatment 2 (EG-HZ-002), Treatment 3 (EG-HZ-003)
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- EyeGene Inc.
Postherpetic Neuralgia ( PHN ), Lymphatic System Disorder
Early Screening Markers of Herpes Zoster Neuralgia
Herpes zoster (HZ), especially postherpetic neuralgia, is one of the most typical types of clinical neuralgia. The incidence rate of HZ in China is approximately 7.7%. Among them, 29.8% of HZ patients eventually develop PHN.
- Trial name
- NCT07038707
- Testing
- Extract the serum and feces of the patients for standard screening of early biomarkers, Meningeal lymphatic vessel imaging
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Varicella Zoster Infection
VZV Vaccine for Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is well-established therapy for patients with malignant hematological diseases. Varicella zoster virus (VZV) reactivation, clinically manifested as herpes zoster (HZ), is a major…
- Trial name
- VZIDST (NCT02329457)
- Testing
- Zostavax, Normal Saline
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong
Herpes Zoster
Occlusion vs Standard Treatment for the Treatment of Herpes Zoster
This study evaluates the addition of occlusive dressings (hydrocolloids) or topical silicone gel in the treatment of shingles (herpes zoster).
- Trial name
- NCT04258930
- Testing
- Aluminum sulphate and calcium acetate drying soaks, Topical sterile silicone gel for wounds, Hydrocolloid dressing
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.
Vaccine, Varicella-zoster Virus
Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial
Immunocompromised individuals, such as patients with multiple sclerosis (MS) or diseases of the neuromyelitis optica spectrum (NMOSD) treated with an anti-CD20 monoclonal antibody, present an increased risk of shingles.
- Conditions
- Vaccine, Varicella-zoster Virus, Multiple Sclerosis, Spectrum Disease Neuromyelitis Optica
- Trial name
- TACTIC (NCT07818356)
- Testing
- Two-dose M0-M2 vaccination schedule, Two-dose M0-M6 vaccination schedule
- Where
- 24 sites in France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Toulouse
Herpes Zoster (HZ)
Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
This phase 1 study in China will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.
- Trial name
- NCT06874842
- Testing
- Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Measles, Mumps
Immune Responses to Two Dose Varivax +/- MMR-II
This study will test the safety and how well the body's immune system responds to a live, but weakened varicella (chickenpox) vaccine, known as Varivax, given with and without ProQuad, another measles, mumps, rubella, and…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00258726
- Testing
- MMR-II, Pro-Quad, Varivax
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009)
This study compared the safety and tolerability profile of a higher potency investigational vaccine to that of the investigational vaccine at a lower potency dose.
- Trial name
- NCT00092417
- Testing
- Comparator: Varicella Zoster Virus Vaccine
- Volunteers
- 695 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postherpetic Neuralgia, Neuropathic Pain
Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia
This observational study aims to compare the effectiveness of ultrasound-guided erector spinae plane (ESP) block and transcutaneous radiofrequency (RF) treatment in patients with postherpetic neuralgia.
- Conditions
- Postherpetic Neuralgia, Neuropathic Pain, Herpes Zoster
- Trial name
- NCT07400640
- Testing
- Erector Spinae Plane Block
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Diskapi Teaching and Research Hospital
Acute Herpes Zoster
Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation
Background: Herpes zoster (HZ) is an acute dermatological condition caused by the varicella-zoster virus. Its onset is characterized by severe pain, imposing significant physical and psychological burdens on patients.
- Trial name
- NCT07515885
- Testing
- Acupuncture, Valacyclovir, pregabalin and mecobalamin
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Dexiong Han